PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026European journal of medical research0 citationsOpen Access

PD-L1 status on circulating tumor cells: a promising predictor in advanced lung cancer with PD-1/PD-L1 immunotherapies

View Full Paper
WXWei XiaLCL H ChenZYZhonglin Yang

Key Points

  • To evaluate the significance of PD-L1 status on circulating tumor cells as a predictor for treatment outcomes in advanced lung cancer during immunotherapy.
  • Retrospective analysis of advanced lung cancer cases
  • Assessment of PD-L1 expression on circulating tumor cells
  • Data collected from clinical records
  • PD-L1 status on circulating tumor cells correlates with patient response to PD-1/PD-L1 immunotherapies
  • High PD-L1 expression indicates better treatment outcomes in advanced lung cancer cases

Abstract

The study was approved by the Medical Ethics Committee of Fourth Affiliated Hospital of Soochow University, with ethics approval number 220154 on 23th January, 2022 and retrospectively registered under clinical trial number ChiCTR2500096312 on 21th January, 2025.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Xia et al. (2026) studied this question.

synapsesocial.com/papers/6980ffd6c1c9540dea8129c6https://doi.org/10.1186/s40001-026-03945-5
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial2019 · 2,293 citations
  2. 2Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients2018 · 89 citations
  3. 3Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis2020 · 85 citations
  4. 4PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology2019 · 11 citations
  5. 5Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).2015 · 148 citations